SCHEMBL861948

SCHEMBL861948

COc1cc2c(N3CCOc4ccc(-c5cnc6nc(N)[nH]c6c5)cc4C3)ncnc2cc1Br

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 5/20 0.39
GAK O14976 2/20 0.39
ALDH1A1 P00352 5/20 0.37
CYP1A2 P05177 5/20 0.37
CYP3A4 P08684 5/20 0.37
CYP2C19 P33261 5/20 0.37
LMNA P02545 4/20 0.37
HIF1A Q16665 4/20 0.37
CLK4 Q9HAZ1 4/20 0.37
MEN1 O00255 3/20 0.37
TSHR P16473 3/20 0.37
KMT2A Q03164 3/20 0.37
MAPK1 P28482 3/20 0.37
TP53 P04637 1/20 0.37
ACHE P22303 3/20 0.36
BACE1 P56817 3/20 0.36
CYP2D6 P10635 3/20 0.34
USP2 O75604 3/20 0.34
KDM4E B2RXH2 1/20 0.34
HPGD P15428 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL861966 0.94 PDE10A (0.45) PDE10AGAKACHEBACE1PDGFRB
SCHEMBL861574 0.87 CYP1A2 (0.45) GAKALDH1A1CYP1A2CYP3A4CYP2C19
SCHEMBL856692 0.87 PIK3CA (0.33) GAKALDH1A1CYP1A2CYP3A4CYP2C19
SCHEMBL856733 0.86 HTT (0.41) ALDH1A1CYP1A2CYP3A4CYP2C19LMNA
SCHEMBL858661 0.86 LMNA (0.41) ALDH1A1CYP1A2CYP3A4CYP2C19LMNA
SCHEMBL855807 0.84 PIK3CA (0.45) PDE10AGAKALDH1A1CYP1A2CYP3A4
SCHEMBL857942 0.84 GRIA1 (0.40) ALDH1A1CYP1A2CYP3A4CYP2C19LMNA
SCHEMBL856484 0.84 CYP3A4 (0.39) ALDH1A1CYP1A2CYP3A4CYP2C19LMNA
SCHEMBL859546 0.83 HTT (0.39) ALDH1A1CYP1A2CYP3A4CYP2C19LMNA
SCHEMBL859609 0.82 NCF1 (0.42) PDE10AKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8648066-B2 Benzoxazepines as inhibitors of PI3K/mTOR and methods of their use and manufacture EXELIXIS, INC. (US) 2014-02-11 US claimed
US-20140080810-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2014-03-20 US disclosed
US-20140080810-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2014-03-20 US disclosed
US-20140080810-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2014-03-20 US disclosed
US-8648066-B2 Benzoxazepines as inhibitors of PI3K/mTOR and methods of their use and manufacture EXELIXIS, INC. (US) 2014-02-11 US disclosed
US-8648066-B2 Benzoxazepines as inhibitors of PI3K/mTOR and methods of their use and manufacture EXELIXIS, INC. (US) 2014-02-11 US disclosed
US-8648066-B2 Benzoxazepines as inhibitors of PI3K/mTOR and methods of their use and manufacture EXELIXIS, INC. (US) 2014-02-11 US disclosed
EP-2640366-A2 BENZOXAZEPINES AS INHIBITORS OF PI3K/MTOR AND METHODS OF THEIR USE AND MANUFACTURE Exelixis, Inc. (US) 2013-09-25 EP disclosed
WO-2012068096-A2 BENZOXAZEPINES AS INHIBITORS OF PI3K/MTOR AND METHODS OF THEIR USE AND MANUFACTURE EXELIXIS, INC. (US) 2012-05-24 WO disclosed
EP-2432779-A1 BENZOXAZEPINES BASED P13K/MT0R INHIBITORS AGAINST PROLIFERATIVE DISEASES Exelixis, Inc. (US) 2012-03-28 EP disclosed
US-20100298290-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2010-11-25 US disclosed
US-20100298290-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2010-11-25 US disclosed
US-20100298290-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2010-11-25 US disclosed
WO-2010135524-A1 BENZOXAZEPINES BASED P13K/MT0R INHIBITORS AGAINST PROLIFERATIVE DISEASES EXELIXIS, INC. (US) 2010-11-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298290-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture MTOR, RICTOR, PIK3CA PDE10A 758/4885GAK 497/4885ALDH1A1 3395/4885
US-20140080810-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture MTOR, RICTOR, PIK3CA PDE10A 663/4885GAK 455/4885ALDH1A1 3049/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.